Fiche publication
Date publication
juin 2025
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
,
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Chi KN, McKay RR, Sandhu S, Arranz JA, Barthélémy P, Hadaschik B, Matsubara N, Shore ND, Ye D, Cascella T, Irincheeva I, Kreiser S, Thiery-Vuillemin A, Rathkopf DE
Lien Pubmed
Résumé
There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still be driven by AR signaling. BMS-986365 is a heterobifunctional, orally bioavailable ligand-directed degrader that targets the AR through a first-in-class dual mechanism of AR degradation and antagonism. Here, we present the study design of rechARge, a phase III, randomized, multicenter, adaptive, two-part, open-label trial evaluating BMS-986365 versus investigator's choice of therapy comprising either docetaxel or a switch to an alternative ARPI (abiraterone or enzalutamide) in patients with mCRPC whose disease has progressed after treatment with one prior ARPI. The primary study objective is to compare the efficacy and safety of BMS-986365 versus investigator's choice of therapy. Approximately 960 patients will be enrolled. www.clinicaltrials.gov identifier is NCT06764485.
Mots clés
BMS‑986365, androgen receptor, clinical trial, ligand-directed degrader, metastatic castration resistant prostate cancer, phase III, protein degradation, protocol
Référence
Future Oncol. 2025 06 2;:1-7
